Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study

被引：0
作者：
Chao Xu
Xiaoli Xie
Ning Kang
Huiqing Jiang
机构：
[1] The Second Hospital of Hebei Medical University,Department of Gastroenterology
[2] Handan Central Hospital,Department of Gastroenterology
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Locally advanced gastric cancer; Apatinib; Programmed cell death protein 1 inhibitor; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4091 / 4099
页数：8
相关论文
共 50 条
  • [31] Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial
    Hu, Xiang
    Chen, Lin
    Du, Yian
    Fan, Biao
    Bu, Zhaode
    Wang, Xin
    Ye, Yingjiang
    Zhang, Zhongtao
    Xiao, Gang
    Li, Fei
    He, Qingsi
    Li, Guoli
    Shen, Xian
    Xiong, Bin
    Zhu, Liming
    Liu, Jiwei
    Liu, Lian
    Wu, Tao
    Zhou, Jing
    Zhang, Jun
    Zhao, Gang
    Wang, Xulin
    Liang, Pin
    Wang, Xinxin
    Zhang, Yan
    Wu, Xiaojiang
    Zhang, Ji
    Ji, Xin
    Zong, Xianglong
    Fu, Tao
    Jia, Ziyu
    Ji, Jiafu
    CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (02) : 144 - 148
  • [32] Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases
    Shi, Min
    Yang, Zhongyin
    Lu, Sheng
    Liu, Wentao
    Ni, Zhentian
    Yao, Xuexin
    Hua, Zichen
    Feng, Runhua
    Zheng, Yanan
    Wang, Zhenqiang
    Sah, Birendra Kumar
    Chen, Mingmin
    Zhu, Zhenglun
    He, Changyu
    Li, Chen
    Zhang, Jun
    Yan, Chao
    Yan, Min
    Zhu, Zhenggang
    BMC CANCER, 2021, 21 (01)
  • [33] S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
    Lu, Yiming
    Liu, Zanchao
    Zhang, Jun
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (03) : 159 - 164
  • [34] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
    Dai, Yu-Hong
    Yu, Xiong-Jie
    Xu, Hui-Ting
    Zhuang, Liang
    Zhang, Ming-Sheng
    Zou, Yan-Mei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xiang-Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [35] Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
    Yin, Bin
    Luo, Wei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [36] The efficacy and safety of apatinib combined with S-1 for advanced gastric cancer: A systematic review and meta-analysis
    Chen, Xing
    Wan, Lifu
    He, Yao
    Zhang, Qin
    Zheng, Xiaoyuan
    MEDICINE, 2024, 103 (21) : E38272
  • [37] DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
    Jaewon Hyung
    Hyungwoo Cho
    Hyung-Don Kim
    Young Soo Park
    Meesun Moon
    Min-Hee Ryu
    Yoon-Koo Kang
    Gastric Cancer, 2024, 27 : 110 - 117
  • [38] DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
    Hyung, Jaewon
    Cho, Hyungwoo
    Kim, Hyung-Don
    Park, Young Soo
    Moon, Meesun
    Ryu, Min-Hee
    Kang, Yoon-Koo
    GASTRIC CANCER, 2023, 27 (1) : 110 - 117
  • [39] The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China A meta-analysis of randomized controlled trials
    Liu, Yan
    Zhou, Changchun
    Zhang, Kai
    Feng, Yikuan
    Zhang, Ruihua
    MEDICINE, 2018, 97 (47)
  • [40] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Wang, Junyun
    Zhu, Mingyue
    Bai, Zhigang
    Zhao, Baoyi
    Zhang, Jun
    Yin, Jie
    Yang, Xiaobao
    Liu, Zongzhi
    Zhang, Zhongtao
    Deng, Wei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2597 - 2608
12345